| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Capps Kathleen S. | Executive Director of Accounting, Controller (Principal Accounting Officer) | C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN | /s/ Matthew Kowalsky as attorney-in-fact | 03 Dec 2025 | 0002085127 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ENTA | Common Stock | Tax liability | $1,200 | -85 | -0.95% | $14.12 | 8,907 | 01 Dec 2025 | Direct | F1 |
| transaction | ENTA | Common Stock | Sale | $2,890 | -207 | -2.3% | $13.96 | 8,700 | 02 Dec 2025 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Represents the number of shares of ENTA common stock forfeited by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 19, 2021. |
| F2 | Represents shares sold by the reporting person to cover withholding taxes due as a result of settlement of a portion of the restricted stock unit award granted on November 27, 2024, as required pursuant to the terms of the award. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person. |
Executive Director of Accounting, Controller (Principal Accounting Officer)